^
Association details:
| Biomarker: | C4G elevation + PRO-C3 underexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 3091: Liquid biopsy reflecting a T-cell permissive tumor microenvironment identifies metastatic melanoma patients responding to immune checkpoint inhibitor therapy
Published date:
06/11/2020
Excerpt:
When combining high C4G with low PRO-C3, the HR dropped to 0.30 (95%CI: 0.15-0.60, p=0.0006)...have an even better chance of responding compared to high C4G levels alone . If validated, this suggests that specific collagen remodeling biomarkers (C4G+PRO-C3) have potential for predicting response to ICI’s in clinical cancer trials.
DOI:
10.1158/1538-7445.AM2020-3091
